Get the Stockscreener App
6.11
3.78%
-0.24
After Hours:
6.20
0.09
+1.47%
Ardelyx Inc stock is traded at $6.11, with a volume of 2.32M.
It is down -3.78% in the last 24 hours and up +1.50% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$6.35
Open:
$6.35
24h Volume:
2.32M
Relative Volume:
0.59
Market Cap:
$1.51B
Revenue:
$427.68M
Net Income/Loss:
$-58.06M
P/E Ratio:
-25.65
EPS:
-0.2382
Net Cash Flow:
$-37.50M
1W Performance:
-1.93%
1M Performance:
+1.50%
6M Performance:
+12.73%
1Y Performance:
+54.29%
1-Day Range:
$6.10
$6.37
1-Week Range:
$6.03
$6.44
52-Week Range:
$3.49
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
6.11 | 1.57B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx (ARDX) price target increased by 12.82% to 13.46 - MSN
Ardelyx chief patient officer sells $43,803 in shares By Investing.com - Investing.com Canada
Ardelyx chief patient officer sells $43,803 in shares - Investing.com
Tax-related Ardelyx (ARDX) insider sale covers RSU withholding needs - Stock Titan
Ardelyx (ARDX) CFO executes 1,455-share tax sell-to-cover after RSU vest - Stock Titan
Ardelyx (ARDX) officer’s RSU vesting triggers 2,306-share tax sell - Stock Titan
Ardelyx (ARDX) HR chief sells 1,846 shares to cover RSU taxes - Stock Titan
Ardelyx (ARDX) Chief Commercial Officer sells 7,998 shares to cover RSU taxes - Stock Titan
Ardelyx (ARDX) chief business officer logs 7,248-share tax sell-to-cover - Stock Titan
Ardelyx (ARDX) Chief Patient Officer sells 6,989 shares to cover RSU taxes - Stock Titan
Ardelyx (ARDX) CEO Raab executes 54,748-share RSU tax sell-to-cover - Stock Titan
Ardelyx president & CEO Michael Raab sells $261,612 of ARDX stock - Investing.com India
What Triggered Ardelyx's Post-Earnings Plunge - Kavout
Ardelyx Earnings Call Highlights Rapid Growth, Rising Costs - TipRanks
ARDX (NASDAQ: ARDX) files Form 144 for 24,986 RSUs vesting - Stock Titan
ARDX (NASDAQ: ARDX) reports 5,355 RSUs vest; insider sales noted - Stock Titan
James Parker Brady files Form 144 for 6,216 ARDX shares (ARDX) - Stock Titan
Proposed Common Stock Sale by ARDX Affiliate (NASDAQ: ARDX) - Stock Titan
ARDX (NASDAQ) insider reports 10,388 RSUs vesting; prior sales 4,991 shares - Stock Titan
Michael Raab reports multiple ARDX share sales (ARDX) and RSU vesting - Stock Titan
ARDX (NASDAQ: ARDX) files Form 144 for 7,771 vested RSUs and lists recent insider sales - Stock Titan
Ardelyx Insider Sold Shares Worth $261,612, According to a Recent SEC Filing - Moomoo
Insider sale reported for ARDX (ARDX): 24,041 RSU shares vest - Stock Titan
Ardelyx (ARDX) CEO sells 41,666 shares in 10b5-1 trade, exercises options - Stock Titan
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 - The Manila Times
A Look At Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Data Strengthens Safety And Efficacy Profile - simplywall.st
Ardelyx, Inc.Common Stock (NQ: ARDX - The Chronicle-Journal
Ardelyx (ARDX) Is Down 8.1% After New Long-Term XPHOZAH Dialysis DataHas The Bull Case Changed? - simplywall.st
Janus Henderson (ARDX) discloses 8.37M‑share, 3.4% position in Ardelyx - Stock Titan
ARDX Stock Chart | ARDELYX INC (NASDAQ:ARDX) - ChartMill
ETFs Investing in Ardelyx, Inc. Stocks - TradingView
Ardelyx, Inc. $ARDX Stock Position Increased by Vanguard Group Inc. - MarketBeat
State Street (ARDX) reports 13.6M-share | 5.5% stake via advisory entities - Stock Titan
TradingKey - TradingKey
Assessing Ardelyx (ARDX) Valuation After New Long Term XPHOZAH Safety Data Presentation - simplywall.st
Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis PatientsWhat's Changed - Yahoo Finance
Why Ardelyx (ARDX) Is Up 10.3% After New Long-Term XPHOZAH Dialysis Data And What's Next - simplywall.st
Ardelyx: Low Price, But High Implied Valuation (NASDAQ:ARDX) - Seeking Alpha
Ardelyx, Inc. (ARDX) Investor Outlook: Analyzing The 134% Potential Upside - DirectorsTalk Interviews
Ardelyx presents long-term safety data for XPHOZAH at NKF meeting By Investing.com - Investing.com South Africa
Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance - Yahoo Finance
Ardelyx presents long-term safety data for XPHOZAH at NKF meeting - Investing.com
Dialysis drug cut phosphate without shifting other electrolytes in trials - Stock Titan
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - TMX Newsfile
Ardelyx (ARDX) Q1 2026 Earnings Transcript - AOL.com
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
Ardelyx (NASDAQ:ARDX) Strengthens Amid Biotech Momentum - Kalkine Media
Ardelyx, Inc. (NASDAQ:ARDX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Moomoo
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end - MSN
A Look At Ardelyx (ARDX) Valuation After Strong Q1 Results And Updated 2026 Guidance - simplywall.st
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):